{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:36:51Z","timestamp":1793137011207,"version":"4.5.0"},"reference-count":21,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"abstract":"<p>Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.<\/p>","DOI":"10.17925\/hi.2023.17.1.2","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T10:16:28Z","timestamp":1688206588000},"page":"2","source":"Crossref","is-referenced-by-count":6,"title":["Mavacamten, an Alternative to Septal Reduction Therapy for Patients with Hypertrophic Cardiomyopathy"],"prefix":"10.17925","volume":"17","author":[{"given":"Milind Y","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel Hajj","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Hypertrophic Cardiomyopathy Center, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7274","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults.\n                      Circulation\n                      . 1995;92:785\u20139. DOI: 10.1161\/01.cir.92.4.785","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Varnava AM, Elliott PM, Baboonian C, et al. Hypertrophic cardiomyopathy: Histopathological features of sudden death in cardiac troponin T disease.\n                      Circulation\n                      . 2001;104:1380\u20134. DOI: 10.1161\/hc3701.095952","DOI":"10.1161\/hc3701.095952"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Elliott P, McKenna WJ. Hypertrophic cardiomyopathy.\n                      Lancet\n                      . 2004;363:1881\u201391. DOI: 10.1016\/S0140-6736(04)16358-7","DOI":"10.1016\/S0140-6736(04)16358-7"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Maron BJ. Hypertrophic cardiomyopathy: A systematic review.\n                      JAMA\n                      . 2002;287:1308\u201320. DOI: 10.1001\/jama.287.10.1308","DOI":"10.1001\/jama.287.10.1308"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review.\n                      J Am Coll Cardiol\n                      . 2022;79:390\u2013414. DOI: 10.1016\/j.jacc.2021.11.021","DOI":"10.1016\/j.jacc.2021.11.021"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Coats CJ, Pavlou M, Watkinson OT, et al. Effect of Trimetazidine dihydrochloride therapy on exercise capacity in patients with Nonobstructive hypertrophic cardiomyopathy: A randomized clinical trial.\n                      JAMA Cardiol\n                      . 2019;4:230\u20135. DOI: 10.1001\/jamacardio.2018.4847.","DOI":"10.1001\/jamacardio.2018.4847"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Olivotto I, Camici PG, Merlini PA, et al. Efficacy of Ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study.\n                      Circ Heart Fail\n                      . 2018;11:e004124. DOI: 10.1161\/CIRCHEARTFAILURE.117.004124.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Andries G, Yandrapalli S, Naidu SS, Panza JA. Novel Pharmacotherapy in hypertrophic cardiomyopathy.\n                      Cardiol Rev\n                      . 2018;26:239\u201344. DOI: 10.1097\/CRD.0000000000000211.","DOI":"10.1097\/CRD.0000000000000211"},{"key":"ref9","unstructured":"ClinicalTrials.gov. Evaluating the effect of spironolactone on hypertrophic cardiomyopathy Clinicaltrials.Gov Identifier: Nct02948998. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02948998 (Date last accessed: 23 May 2023)."},{"key":"ref10","unstructured":"ClinicalTrials.gov. . Efficacy, safety, and tolerability of Perhexiline in subjects with hypertrophic cardiomyopathy and heart failure. Clinicaltrials.Gov Identifier: Nct02431221. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02431221 (Date last accessed: 23 May 2023)."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Axelsson A, Iversen K, Vejlstrup N, et al. Efficacy and safety of the angiotensin II receptor blocker Losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.\n                      Lancet Diabetes Endocrinol\n                      . 2015;3:123\u201331. DOI: 10.1016\/S2213-8587(14)70241-4.","DOI":"10.1016\/S2213-8587(14)70241-4"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Stern JA, Markova S, Ueda Y, et al. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy.\n                      PLoS One\n                      . 2016;11:e0168407. DOI: 10.1371\/journal.pone.0168407","DOI":"10.1371\/journal.pone.0168407"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial.\n                      Lancet\n                      . 2020;396:759\u201369. DOI: 10.1016\/S0140-6736(20)31792-X","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.\n                      J Am Coll Cardiol\n                      . 2022;80:95\u2013108. DOI: 10.1016\/j.jacc.2022.04.048","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"ref15","unstructured":"ClinicalTrials.gov. A long-term safety extension study of Mavacamten in adults who have completed MAVERICK-HCM or EXPLORER-HCM. ClinicalTrials.gov Identifier: NCT03723655. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03723655 (Date last accessed: 23 May 2023)."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Desai MY, Owens A, Geske JB, et al. Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: Outcomes through 32-weeks.\n                      Circulation\n                      . 2023;147:850\u201363. DOI: 10.1161\/CIRCULATIONAHA.122.062534","DOI":"10.1161\/CIRCULATIONAHA.122.062534"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Liebregts M, Vriesendorp PA, Mahmoodi BK, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy.\n                      JACC Heart Fail\n                      . 2015;3:896\u2013905. DOI: 10.1016\/j.jchf.2015.06.011","DOI":"10.1016\/j.jchf.2015.06.011"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Mentias A, Smedira NG, Krishnaswamy A, et al. Survival after septal reduction in patients > 65 years old with obstructive hypertrophic cardiomyopathy.\n                      J Am Coll Cardiol\n                      . 2023;81:105\u201315. DOI: 10.1016\/j.jacc.2022.10.027","DOI":"10.1016\/j.jacc.2022.10.027"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Maron BJ, Dearani JA, Ommen SR, et al. Low operative mortality achieved with surgical septal myectomy: Role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction.\n                      J Am Coll Cardiol\n                      . 2015;66:1307\u20138. DOI: 10.1016\/j.jacc.2015.06.1333","DOI":"10.1016\/j.jacc.2015.06.1333"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Desai MY, Wolski K, Owens A, et al. Study design and rationale of VALOR-HCM: evaluation of Mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.\n                      Am Heart J\n                      . 2021;239:80\u20139. DOI: 10.1016\/j.ahj.2021.05.007.","DOI":"10.1016\/j.ahj.2021.05.007"},{"key":"ref21","unstructured":"ClinicalTrials.gov. A study of Mavacamten in non-obstructive hypertrophic cardiomyopathy (Odyssey_Hcm). Clinicaltrials.Gov Identifier: Nct05582395. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05582395 (Date last accessed: 23 May 2023)."}],"container-title":["Heart International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchcardio.com\/cardiovascular-disease\/journal-articles\/mavacamten-an-alternative-to-septal-reduction-therapy-for-patients-with-hypertrophic-cardiomyopathy\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:58:12Z","timestamp":1764745092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchcardio.com\/cardiovascular-disease\/journal-articles\/mavacamten-an-alternative-to-septal-reduction-therapy-for-patients-with-hypertrophic-cardiomyopathy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["HI.2023.17.1.2"],"URL":"https:\/\/doi.org\/10.17925\/hi.2023.17.1.2","relation":{},"ISSN":["2036-2579"],"issn-type":[{"value":"2036-2579","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}